NCT Number: NCT00000625
A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3
To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
Looking for future studies?
Notify MeKey information
Conditions
Age range
12 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Puerto Rico-AIDS CRS, San Juan, Puerto Rico
About this study
Patients are randomized to receive AZT alone, AZT and ddI, AZT and ddC, or ddI alone for at least 2 years. Patients who develop AIDS or whose CD4 count falls to 50 percent or less of baseline are crossed over to another treatment arm.
PER AMENDMENT 4/5/95: Study treatment will be available until 10/31/95 at the latest for patients still taking study medications on 4/30/95, so that follow-up trials may be completed and approved.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Concurrent Medication:
Allowed:
- PCP prophylaxis, M. tuberculosis prophylaxis, short courses of acyclovir, chronic suppressive acyclovir, pneumovax or Hib vaccine, antibiotics, rEPO and G-CSF for grade 3 or worse anemia and neutropenia, systemic corticosteroids for < 21 days, regularly prescribed medications, and vitamins or herbal therapies.
Patients must have:
- HIV infection without AIDS with CD4 200-500 cells/mm3.
PER AMENDMENT 4/5/95:
- Patients must have remained on ACTG 175 study treatment through 4/30/95 and meet toxicity management criteria for continuing treatment. Subjects taking ACTG 175 crossover treatment are eligible.
Exclusion criteria
Co-existing Condition:
Patients with the following conditions are excluded:
- Current AIDS-related condition other than minimal KS, grade 2 or worse peripheral neuropathy, and malignancy requiring systemic therapy.
Concurrent Medication:
Excluded:
- Other anti-HIV drugs, biologic response modifiers other than rEPO and G-CSF, systemic cytotoxic chemotherapy, chronic systemic corticosteroids, or any drug that affects AZT glucuronidation or clearance.
Concurrent Treatment:
Excluded:
- Radiotherapy other than limited local therapy to skin.
Patients with the following prior conditions are excluded:
- AIDS-related condition other than minimal KS; intolerance to AZT, ddI, or ddC at study doses; and acute or chronic pancreatitis.
Prior Medication:
Excluded:
- Acute therapy for an infection or other medical illness within the past 14 days.
Current alcohol abuse.
Treatment and study plan
Zalcitabine
DrugDidanosine
DrugSponsors and collaborators
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
Collaborators
- Bristol-Myers Squibb
- Glaxo Wellcome
Registry information
Important dates
- Study completion
- 1995
- First posted
- Aug 31, 2001
- Registry last updated
- Nov 2, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)
NCT00000810
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Stanford, California, United States
View Trial DetailsA Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy
NCT00000842
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Los Angeles, California, United States
View Trial DetailsA Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen
NCT00000782
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Palo Alto, California, United States
View Trial DetailsComparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection
NCT00000739
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Long Beach, California, United States
View Trial Details